How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Search
Filter
6,241 - 6,260 of 15,468 Results
-
-
Military Doctors In Crosshairs Of A Budget Battle
Details of the reductions have not yet been announced, but in 2017 Congress ordered mandated changes to make the military health system more efficient.
By Jordan Rau -
Why Measles Hits So Hard Within N.Y. Orthodox Jewish Community
More than 275 people — mostly in Orthodox Jewish communities — have been infected since the disease began spreading in October. That’s about half of the confirmed cases in 11 states that were reported nationwide by the federal officials since January 2018.
-
FDA Announces Sweeping Plan To Review Safety Of Surgical Staplers
The FDA said it might reclassify the widely used devices featured in a recent Kaiser Health News investigation.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Always Connected With Thousands Of ‘Friends’ — Yet Feeling All Alone
Millennials and Gen Zers say they often feel isolated even when surrounded by friends — both real and virtual.
-
As Hospitals Post Price Lists, Consumers Are Asked To Check Up On Them
Most hospitals appear to be complying with the federal rule to post their prices online. Yet there is little follow-up by the government or industry and debate continues about whether the price lists are creating more confusion than clarity among consumers.
-
Lawmakers United Against High Drug Prices Bare Partisan Teeth
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
By Rachel Bluth -
Podcast: KHN’s ‘What The Health?’ What’s Next For The FDA?
Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss the resignation of Food and Drug Administration Commissioner Scott Gottlieb, the latest on federal and state efforts to shore up the Affordable Care Act; and how public health officials plan to persuade parents who are reluctant to vaccinate their kids. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
-
Hidden FDA Reports Detail Harm Caused By Scores Of Medical Devices
The Food and Drug Administration has let medical device companies file reports of injuries and malfunctions outside a widely scrutinized public database, leaving doctors and medical sleuths in the dark.
-
A Mumps Quarantine In La. May Encroach On Rights Of Detained Immigrants
A recent outbreak at a Louisiana center triggered public health protections, but some immigration lawyers are crying foul.
By Shefali Luthra and Julie Appleby -
Cities And Counties Unlikely To Heed FDA Warning On Importing Foreign Drugs
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent “unapproved” and “misbranded” drugs to U.S. consumers, jeopardizing their safety.
-
California Looks To Lead Nation In Unraveling Childhood Trauma
The Golden State, in a movement spearheaded by its first-ever surgeon general, stands to become a vanguard for the nation in tracing adverse childhood experiences, or ACEs, to the onset of physical and mental illness. But what can a pediatrician, with her 15-minute time slots and extensive to-do list, do about the ills of an absent parent or a neighborhood riddled with gun violence?
-
The Promise Of Youth, The Reality Of Aging
Patients Experiment With Prescription Drugs To Fight Aging
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
-
Patients Question How FDA Approves Medical Devices
High-profile failures of implantable medical devices — such as certain hip joints and pelvic mesh — have prompted the Food and Drug Administration to revise its assessment process.
-
This Time When My Water Breaks, Take Me To A Hospital Without Surprise Bills
New research shows how an experience with surprise medical bills can guide patients’ future decision-making.
By Rachel Bluth -
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes
A KHN database shows that $58 million flowed from drugmakers to patient groups running national ads.
-
Texas Lawmakers Take Aim At Surprise Medical Bills
A proposed state law with bipartisan, bicameral support is on the move in Texas. It would force hospitals and insurers to settle surprise bills — instead of relying on patients to start the mediation process. The KHN/NPR "Bill of the Month" series is a catalyst for the effort.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Watch: Big Week For Drug Pricing Debate Featured On C-SPAN
KHN correspondent Emmarie Huetteman appeared on the C-SPAN program “Washington Journal,” where she fielded viewers’ calls about high drug prices and industry criticism.